Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: A case report

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 732-734

  Higuchi, Yuko ^a   Sumiyoshi, Tomiki ^a   Kawasaki, Yasuhiro ^a   Ito, Toru ^a   Seo, Tomonori ^a   Suzuki, Michio ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; SULPIRIDE; TANDOSPIRONE;

ADD ON THERAPY; ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; COGNITION; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; HOSPITAL READMISSION; HUMAN; LETTER; MISMATCH NEGATIVITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ACOUSTIC STIMULATION; ADULT; COGNITION DISORDERS; EVOKED POTENTIALS; FEMALE; HUMANS; ISOINDOLES; PIPERAZINES; PYRIMIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 78649349597     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181faa57d     Document Type: Letter

References (20)

1. Baldeweg T, Klugman A, Gruzelier J, et al. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res. 2004;69:203-217.
2. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62:127-136.
3. Kawakubo Y, Kasai K. Support for an association between mismatch negativity and social functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1367-1368.
4. Matsui M, Sumiyoshi T, Arai H, et al. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:280-287.
5. Garrido MI, Kilner JM, Stephan KE, et al. The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol. 2009;120:453-463.
6. Rasser PE, Schall U, Todd J, et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr Bull. 2009 [Epub ahead of print].
7. Leung S, Croft RJ, Guille V, et al. Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants. Psychopharmacology (Berl). 2010;208: 233-244.
8. Kahkonen S, Makinen V, Jaaskelainen IP, et al. Serotonergic modulation of mismatch negativity. Psychiatry Res. 2005;138: 61-74.
9. Heekeren K, Daumann J, Neukirch A, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008;199: 77-88.
10. Oranje B, Jensen K, Wienberg M, et al. Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention. Int J Neuropsychopharmacol. 2008;11: 453-463.
11. Wienberg M, Glenthoj B, Jensen K, et al. A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers. J Psychopharmacol. 2009.
12. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158:1722-1725.
13. Sumiyoshi T, Matsui M, Yamashita I, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000;20: 386-388.
14. Sumiyoshi T, Higuchi Y, Itoh T, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res. 2009;172:180-183.
15. Kaneda Y, Sumiyoshi T, Keefe R, et al. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. 2007;61:602-609.
16. Lavoie S, Murry MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33:2187-2199.
17. Sumiyoshi T, Park S, Jayathilake K, et al. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95:158-168.
18. Araki T, Yamasue H, Sumiyoshi T, et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:204-208.
19. Javitt DC, Steinschneider M, Schroeder CE, et al. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci \USA. 1996;93:11962-11967.
20. Llado-Pelfort L, Santana N, Artigas F, et al. Postsynaptic 5-HT1A receptors are involved in the excitatory action of 8-OH-DPAT on prefrontal cortex pyramidal neurons. Society for Neuroscience (Chicago). 2009;748:2.